On Tuesday, Dianthus Therapeutics Inc (NASDAQ: DNTH) opened higher 14.67% from the last session, before settling in for the closing price of $39.12. Price fluctuations for DNTH have ranged from $13.36 to $45.46 over the past 52 weeks.
Healthcare Sector giant saw their annual sales surged by 40.14% over the last five years. Company’s average yearly earnings per share was noted -45.14% at the time writing. With a float of $36.43 million, this company’s outstanding shares have now reached $42.85 million.
Dianthus Therapeutics Inc (DNTH) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Dianthus Therapeutics Inc is 15.04%, while institutional ownership is 92.73%. The most recent insider transaction that took place on Dec 04 ’25, was worth 903,600. In this transaction CFO & CBO of this company sold 20,000 shares at a rate of $45.18, taking the stock ownership to the 0 shares. Before that another transaction happened on Dec 04 ’25, when Company’s Officer proposed sale 20,000 for $43.97, making the entire transaction worth $879,400.
Dianthus Therapeutics Inc (DNTH) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.7 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.76) by 0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -45.14% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -17.45% during the next five years compared to 40.14% growth over the previous five years of trading.
Dianthus Therapeutics Inc (NASDAQ: DNTH) Trading Performance Indicators
Check out the current performance indicators for Dianthus Therapeutics Inc (DNTH). In the past quarter, the stock posted a quick ratio of 17.35. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 624.49.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.49, a number that is poised to hit -1.07 in the next quarter and is forecasted to reach -3.63 in one year’s time.
